In Focus: recent therapies in renal cell carcinoma
In our latest In Focus, Prof Brian Rini (Vanderbilt-Ingram Cancer Center, TN, USA) discusses the treatment landscape for people living with renal cell carcinoma (RCC), as well as the current challenges and limitations of current therapies and how he hopes the treatment landscape will evolve over the next 5 years.
FEATURES
Recent therapies in renal cell carcinoma (RCC): an interview with Brian Rini
In this article, Prof Brian Rini discusses recent therapies in RCC, as well as predictions for the future of the treatment landscape.
Infographic: recent therapies in renal cell carcinoma (RCC)
Our recent In Focus has focused on recent therapies for RCC. This infographic summarizes the key points, including available therapies and how the field will evolve.
Local ablative therapies as key treatment options for selected metastatic renal cell carcinoma
In this interview find out about the challenges of treating renal cell carcinoma and her recent research into metastatic renal cell carcinoma pretreated with pazopanib.
This Clinical Trial Protocol, published in Future Oncology, describes the Phase II CaboPoint study that has been designed to evaluate the efficacy and safety of second-line cabozantinib in patients with unresectable, locally advanced or metastatic RCC.
This article reports a real-world US study that aimed to provide an in-depth understanding of treatment patterns, clinical outcomes and patient characteristics in advanced renal cell carcinoma.